Trials / Terminated
TerminatedNCT01977079
Procalcitonin and Threatened Premature Delivery
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Centre Hospitalier Departemental Vendee · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Among all patients hospitalized for Threatened Premature Delivery (TPD), the rate of premature birth (PB) before 37 weeks is about 42%, which reflects the inability to accurately identify patients at high risk of PB. Currently, no clinical or biological marker is recognized as the most reliable in predicting the real risk of AP in case of MAP. The purpose of this study is to improve the knowledge of predictors of preterm delivery compared with conventional blood markers by estimating serum procalcitonin according to premature delivery or not in patients hospitalized for preterm labor .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | procalcitonin |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2013-11-06
- Last updated
- 2025-11-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01977079. Inclusion in this directory is not an endorsement.